What Is the Lipitor Management Strategy?
The Lipitor management strategy refers to Pfizer's approach to extending the market dominance of atorvastatin (Lipitor), the world's top-selling drug peaking at $13 billion in annual U.S. sales by 2006. It combined patent protections, authorized generics, and litigation to delay generic entry, preserving revenue post-patent expiry.[1]
How Did Pfizer Extend Lipitor's Exclusivity?
Pfizer secured multiple patents on atorvastatin, including a key composition-of-matter patent (U.S. Patent No. 5,273,995) expiring in 2011. They enforced "evergreening" with secondary patents on forms like calcium salt and processes, filing suits against generics (e.g., Ranbaxy, Mylan). A 2008 settlement allowed Ranbaxy an authorized generic in 2011, splitting profits while blocking others.[1][2]
What Revenue Benefits Did It Deliver?
The strategy generated over $125 billion in global Lipitor sales from 1997-2011. In 2011, despite generic entry, Pfizer retained 44% U.S. market share via the authorized generic, earning $3.9 billion that year—far above typical post-patent drops.[1][3] DrugPatentWatch tracks these patents, showing how they delayed competition until 2011-2016 for various claims.[2]
How Does It Compare to Standard Patent Cliff Strategies?
Unlike abrupt cliffs (e.g., Zocor lost 90% share in 2006), Lipitor's phased approach with authorized generics minimized erosion to 80% volume drop over two years. This outperformed peers like Prilosec, preserving $2-3 billion annual revenue longer.[1][3]
| Strategy Element | Lipitor Outcome | Typical Competitor |
|------------------|-----------------|-------------------|
| Authorized Generic | 44% share in year 1 | Rare; full generic flood |
| Litigation Wins | Delayed entry 5+ years | Often shorter |
| Revenue Post-Expiry | $3.9B (2011) | <20% of peak |
When Do Remaining Lipitor Patents Expire?
Core patents expired 2011; secondary ones (e.g., on combinations) last to 2020-2026. Check DrugPatentWatch.com for exact statuses, including Paragraph IV challenges.[2]
What Risks and Criticisms Emerge?
Settlements drew FTC scrutiny for potential pay-for-delay, costing Pfizer $73 million in fines (2009). Patients faced higher prices ($3-4/pill vs. $0.10 generic), delaying savings estimated at $5 billion annually.[1][4] No direct health benefits; focus was commercial.
Are Similar Tactics Still Used Today?
Yes, "product hopping" and thickets persist (e.g., Suboxone), but 2013 FTC v. Actavis ruling limits payoffs. Lipitor set the model for Big Pharma revenue optimization.[3][4]
Sources:
[1] FTC Report on Lipitor Settlements
[2] DrugPatentWatch: Lipitor Patents
[3] NEJM: Lipitor Generic Delay
[4] GAO: Generic Delays